In the first half of 2018, 33 companies in the genetic industry were financed, including companies such as Panshengzi, Qihe Technology, Biotech, WeGene, etc., while the financing rounds accounted for 23% in the A and B rounds. It can be seen that the activity of the genetic industry in the market is gradually increasing, and capital is also helping, and a large number of entrepreneurial enterprises are constantly emerging. Previously, China's genetic testing industry has been developing slowly. Before 2014, due to imperfect government supervision system, the industry has been in an unregulated state, so that in February 2014, CFDA and the Health Planning Commission stopped all gene sequencing business, and concentrated on the industry, only approved in March of the same year. Compliance medical institutions apply for pilots, but genetic sequencing projects must be identified. After 2015, the National Health and Family Planning Commission began to gradually approve a number of clinical pilot projects, including genetic disease diagnosis, prenatal screening and diagnosis, preimplantation embryo genetic diagnosis, tumor diagnosis and treatment. In 2016, the country began to launch a precision medicine program, which led to the accelerated development of the entire genetic industry. What is the difference between Chinese and American precision medicine ? The emergence of precision medicine comes from market demand. According to statistics, from 2016 to 2020, the global precision medical market will grow at a rate of 15% per year. It is estimated that the global precision medical market will break through 100 billion in 2020, reaching $105 billion. The large-scale market has led the United States to take the lead in conducting research on precision medicine, which also marks the beginning of precision medical research in developed countries represented by the United States. China's precision medical plan is one year later than the United States, but the government also attaches great importance to precision medicine. The published policy is very intensive and is accelerating the supervision of the industry. At the same time, the country has also proposed key directions such as “queue, big data, biomarkers, precision prevention, and precise treatmentâ€, and is also promoting the standardization of the precision medical industry . Sino-US precision medical care is accelerating, but in the view of Sun Liying, former FDA review leader and former NIH project director, there is still a big gap in the development of precision medicine between China and the United States. First, data security and effectiveness issues. To use data for genetic research, we must consider ethical issues and patient informed issues. This is a consensus that humans have achieved. Therefore, regarding the amount of data, the population from which to do, how to do experimental design, sensitivity data, specific data, what risks may exist, and how to control if there is risk, it should be clear. The United States has done a good job in this respect. At present, China's products still lack relevant data in these areas. Second, compared with China and the United States, China's patent protection and property rights protection are still insufficient. Third, there is a lack of interdisciplinary statistical talent. In Sun Liying's view, if you want to study precision medicine, you must do some statistics. This is an interdisciplinary knowledge that requires interdisciplinary talents, which is precisely the weakness of our country. How to establish a three-way connection between the genetic industry and medical care and health? The downstream of the genetic testing industry is mainly scientific research institutions, pharmaceutical companies, medical institutions, and even cross-border value-added services, and cooperation with insurance companies. The development of the genetic industry will ultimately be applied in the medical field, for the diagnosis and screening of diseases, or for health consultation. Regarding how to establish a three-way connection between the genetic industry and medical care and health, Gu Weihong, founder of Gu Dafu Studio, believes that the connection between the genetic industry and medical care mainly includes the diagnosis and treatment of genetic diseases and tumors, and the intervention of birth defects, so it is necessary to go through hospitals. The doctor goes to connect to the patient and the subject. Since the development of genetic technology is very fast, it is necessary to establish an effective connection in each process in the process of transformation and application. It is very important that the three parties in the application scenario, that is, the detection party-medical party-the examiner, have as much information as possible, and the medical party is very important. (mainly referring to doctors) is the core link. In addition, strengthening the public's understanding of the genetic industry is also an important foundation for the sound development of the entire industry. Among them, the media has played a significant role in this ring. However, there are currently some media misinterpreting and amplifying problems in the industry, and the public lacks reliable sources of information, which will inevitably lead to confusion of information, which will have a negative impact on the development of the entire industry. Professional media and public media should work together to establish effective channels and methods to disseminate scientific information to the public. Regarding the connection between the gene and health fields, she believes that each country is currently in the initial exploration stage. The link between genetics and health counseling and management must be based on adequate and reliable medical data in order to scientifically assess the risk of certain diseases. At the same time, it is necessary to fully consider the impact of the test on the subject, and the ability of the tester and its partners to give the subject the appropriate intervention and management. What is the current state of application of new technologies in genetic testing? artificial intelligence Artificial intelligence is applied to the medical field, including: Al+ auxiliary, Al+ guidance, Al+ health management, Al+ new drug research and so on. The combination of artificial intelligence and the genetic industry includes online genetic counseling. The development of genetic counseling in China was relatively late. In 2015, the Chinese Genetic Society established the Genetic Consulting Branch. With the establishment of academic groups and the promotion of genetic counseling experts and academic leaders, there has gradually been the emergence of genetic counselors. However, most of the genetic counselors are currently in third-party testing institutions. The genetic counselors in the doctors' team have not yet been fully established. Many of them are also the role of genetic counselors at the same time, so they are not efficient. The basic source medical laboratory is doing online genetic counseling services, and has established a small program of the genetic counseling agency to meet the relevant needs of genetic disease patients. According to Xiong Hui, a basic medical laboratory, this program has two functions: one is online genetic counseling, and the genetic counselor answers professional questions; the second is equipped with an AI called “Qiyuan Searchâ€. Auxiliary diagnostic system for intelligent genetic diseases. Blockchain Genetic testing is inseparable from the discussion of big data. Big data is the foundation for drug development or disease control, and only sharing can make gene big data worthwhile. In this, the blockchain can play a huge role. It can solve the trust problem in the use of user health data, solve the concerns of users in traditional centralized storage for data privacy and security issues through distributed computing, so that user health data dispersed in different medical institutions can be safely Legal access and use, so that research institutions can access and "track data changes" to promote people's exploration of disease. The specific application of blockchain in the genetic industry, according to Yuan Jianzhong, general manager of China Pharmaceuticals, China Pharmaceuticals, Ltd., launched a large health data bank LifeCODE based on blockchain technology. Ai platform. LifeCODE. Ai solves the legitimacy and effectiveness of large-health data collection by innovatively applying blockchain technology, creating data interaction value while protecting user privacy, and realizing the property rights and assets of large health data. Probiotics powder have been shown to be good bacteria in the gut, clearing out bad bacteria and also improving the body's immune system. There can be more than 500 types of bacteria in your gut. Probiotics are defined as active microbial products that contain sufficient quantities to alter the gastrointestinal flora of the host to produce beneficial effects. Common probiotics include Lactobifidobacterium, Lactobacillus plantarum, Lactobacillus acidophilus, bifidobacterium longum and so on. Lactobacillus Reuteri,Lactobacillus Rhamnosus,Bifidobacterium Lactis Powder,Lactobacillus Acidophilus,Lactobacillus Plantarum Xi'an Gawen Biotechnology Co., Ltd , https://www.amulyn-bio.com